title: Neoadjuvant chemotherapy cannot be regarded as adequate routine therapy strategy of advanced ovarian cancer.
abstract: Minority vote to statement A5 of the Fourth Ovarian Cancer Consensus Conference, Vancouver 2010, on behalf of the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Germany plus North-Eastern Society of Gyneco-Oncology and the AGO Austria.
authors.affiliation: Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Studiengruppe, Germany. Prof.duBois@googlemail.com
authors.forename: Andreas
authors.initials: A
authors.lastname: du Bois
authors.forename: Christian
authors.initials: C
authors.lastname: Marth
authors.forename: Jacobus
authors.initials: J
authors.lastname: Pfisterer
authors.forename: Philipp
authors.initials: P
authors.lastname: Harter
authors.forename: Felix
authors.initials: F
authors.lastname: Hilpert
authors.forename: Alain G
authors.initials: AG
authors.lastname: Zeimet
authors.forename: Jalid
authors.initials: J
authors.lastname: Sehouli
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D001317:Austria; D003245:Consensus Statements as Topic; D005260:Female; D005858:Germany; D006801:Humans; D020360:Neoadjuvant Therapy; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000473:pathology / Q000628:therapy*; D010818:Practice Patterns, Physicians'; D016387:Women's Health